Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04702763
Other study ID # e-VOG
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 8, 2020
Est. completion date October 30, 2021

Study information

Verified date January 2022
Source Association de Recherche Bibliographique pour les Neurosciences
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to compare measurements obtained through the e-VOG application (mobile application, usable on mobile phones or tablets, to measure eye movements) with measurements from the standard video-oculography device (Eye-Tracker®T2), in patient with Multiple Sclerosis.


Description:

Based on literature, investigators hypothesize that it would be relevant to focus more broadly on subclinical abnormalities of oculomotricity in multiple sclerosis (MS). However, the difficulty of accessing video-oculography platforms (or eye-tracking devices) is probably one of the main limitations to performing this type of assessment. To respond this problem, the "Resources and Skills Center-Multiple Sclerosis" (CRC SEP) team at the Nice University Hospital Center (France) has developed a mobile application (named e-VOG), usable on mobile phones or tablets, to measure eye movements. e-VOG reproduces the classic paradigms of video-oculography to collect data similar to standard video-oculography recording (saccade latency and speed, anti-saccade error rate, presence of fixation abnormalities). e-VOG will not replace standard video-oculography platforms, because its technical characteristics are not as high. But investigators hypothesize that this application could constitute a screening tool for subclinical oculomotor abnormalities, usable by neurologists in consultation, directly on their mobile, which would make it possible to select a smaller population of patients in whom a further exploration by standard video-oculography would be indicated. Memory Center of the Rainier III Gerontologic Center (Princess Grace Hospital - Monaco) is equipped with a standard video-oculography device, also named eye-tracking device (Eye-Tracker®T2), which records eye movements at a high frequency and measures saccades parameters (latency, speed, amplitudes etc...). This study is a collaborative study between the Center Rainier III team and the CRC SEP team in Nice. Its objective will be to compare measurements obtained through the e-VOG application with measurements from the standard video-oculography device.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date October 30, 2021
Est. primary completion date October 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or Female. - 18 years old and above. - referred by a neurologist to perform a video-oculography (Eye-Tracking) examination as part of routine care. - with Multiple Sclerosis (defined according to McDonald's 2017 criteria). - covered by a health insurance system - volunteer, able to give free, informed and written consent. Exclusion Criteria: - General anaesthesia within 3 months. - Neurological, ophthalmological or general pathology preventing the realization of a video-oculography examination. - Oculomotor abnormality detectable on clinical examination by the neurologist prescribing the standard video-oculography examination.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Eye-Tracker®T2 + e-VOG
1st step: eyes movements assessed with standard video-oculography device 2° step: eyes movements assessed with e-VOG digital application Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care
e-VOG + Eye-Tracker®T2
1st step: eyes movements assessed with e-VOG digital application 2° step: eyes movements assessed with standard video-oculography device Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care

Locations

Country Name City State
Monaco Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital Monaco

Sponsors (3)

Lead Sponsor Collaborator
Association de Recherche Bibliographique pour les Neurosciences Centre Hospitalier Princesse Grace, Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

Monaco, 

Outcome

Type Measure Description Time frame Safety issue
Primary Oculomotor profiles concordance Analyze of the concordance of the profiles obtained between the e-VOG digital assessment and the standard video-oculography assessment.
Evaluation criteria: For each assessment, patients will be classified into 3 profiles (Profile 1 = profile without oculomotor abnormality; Profile 2 = intermediate profile with 1 to 2 oculomotor abnormalities; Profile 3: profile with 3 to 4 oculomotor anomalies), based on the observation of 4 parameters (latency / speed / fixation disorders / presence of internuclear ophthalmoplegia), in accordance with the literature standards.
Day 0
Secondary Latency during horizontal reflex saccades Measure of Latency during an horizontal reflex saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device.
Evaluation criteria: latency (reaction time in ms).
Day 0
Secondary Latency during vertical reflex saccades Measure of Latency during a vertical reflex saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device.
Evaluation criteria: latency (reaction time in ms).
Day 0
Secondary Velocity during horizontal reflex saccades Measure of Velocity during an horizontal reflex saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device.
Evaluation criteria: velocity (mean and peak velocity) in °/s.
Day 0
Secondary Velocity during vertical reflex saccades Measure of Velocity during a vertical reflex saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device.
Evaluation criteria: velocity (mean and peak velocity) in °/s.
Day 0
Secondary Inhibition capacity Measure of inhibition capacity performance during an antisaccades" paradigm with e-VOG Compared to the one evaluated with standard video-oculography device.
Evaluation criteria: percentage of errors.
Day 0
Secondary Internuclear ophthalmoplegia (INO) detection Highlight presence/absence of INO with e-VOG Compared to standard video-oculography device.
Evaluation criteria: INO is present if calculated ratio of abducting to adducting eye movement (both mean and peak velocity) is >1.
Day 0
Secondary Fixations impairments detection Highlight presence/absence of Fixations impairments with e-VOG Compared to standard video-oculography device.
Evaluation criteria: presence/absence/frequency of square wave-jerks, nystagmus, flutters.
Day 0
Secondary Impairment of horizontal smooth pursuit Highlight Impairment of horizontal smooth pursuit with e-VOG Compared to standard video-oculography device.
Evaluation criteria: presence/absence of saccade and perturbation.
Day 0
Secondary Impairment of vertical smooth pursuit Highlight Impairment of horizontal smooth pursuit with e-VOG Compared to standard video-oculography device.
Evaluation criteria: presence/absence of saccade and perturbation.
Day 0
Secondary Patient acceptability of the e-VOG digital assessment Comparison of patient acceptability between the e-VOG digital assessment and the standard video-oculography assessment.
Evaluation criteria: satisfaction questionnaire given to the patient at the end of assessments. 2 questions on the difficulty or discomfort felt during the 2 assessments.
Day 0
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4